Osteoprotegerin levels in children with subclinical hypothyroidism.
children and adolescents
osteoprotegerin
subclinical hypothyroidism
Journal
Acta paediatrica (Oslo, Norway : 1992)
ISSN: 1651-2227
Titre abrégé: Acta Paediatr
Pays: Norway
ID NLM: 9205968
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
15
01
2020
revised:
23
03
2020
accepted:
30
03
2020
pubmed:
8
4
2020
medline:
15
5
2021
entrez:
8
4
2020
Statut:
ppublish
Résumé
In this study, we investigated the osteoprotegerin (OPG) and soluble receptor activator of nuclear factor-kappa Β ligand (sRANKL) serum levels in association with thyroid function in children with subclinical hypothyroidism. In 143 children and adolescents with subclinical hypothyroidism and 343 with normal thyroid function, age, height, weight and pubertal status were recorded and TSH, free thyroxine (FT4), anti-thyroid antibodies, OPG and sRANKL were measured in serum. Multiple linear regression was used for the statistical analysis with P < .05. Children with subclinical hypothyroidism had higher TSH and lower FT4 serum levels than the control group (P < .05). Both groups had similar BMI Z-score, OPG and sRANKL serum levels. After multiple regression analysis, in children with subclinical hypothyroidism, OPG was negatively associated with FT4 (P < .05) whilst no association was observed between OPG and sRANKL, as well as between FT4 serum levels and RANKL. Osteoprotegerin levels in children with subclinical hypothyroidism do not differ from those of euthyroid children. However, there is a negative association between FT4 and OPG levels observed only in the SH group. Considering the link between vascular dysfunction and alterations in osteoprotegerin levels, further research is needed to establish the role of childhood subclinical hypothyroidism in the long-term cardiovascular risk.
Substances chimiques
Osteoprotegerin
0
RANK Ligand
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2770-2774Informations de copyright
© 2020 Foundation Acta Paediatrica. Published by John Wiley & Sons Ltd.
Références
Gencer B, Collet TH, Virgini V, et al. Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from 6 prospective cohorts. Circulation. 2012;126(9):1040-1049.
Chaker L, Baumgartner C, den Elzen WP, et al. Subclinical Hypothyroidism and the Risk of Stroke Events and Fatal Stroke: An Individual Participant Data Analysis. J Clin Endocrinol Metab. 2015;100(6):2181-2191.
Biondi B. Cardiovascular effects of mild hypothyroidism. Thyroid. 2007;17(7):625-630.
Owen PJ, Sabit R, Lazarus JH. Thyroid disease and vascular function. Thyroid. 2007;17(6):519-524.
Taddei S, Caraccio N, Virdis A, et al. Impaired endothelium-dependent vasodilatation in subclinical hypothyroidism: beneficial effect of levothyroxine therapy. J Clin Endocrinol Metab. 2003;88(8):3731-3737.
Ittermann T, Thamm M, Wallaschofski H, Rettig R, Volzke H. Serum thyroid-stimulating hormone levels are associated with blood pressure in children and adolescents. J Clin Endocrinol Metab. 2012;97(3):828-834.
Cerbone M, Capalbo D, Wasniewska M, et al. Cardiovascular risk factors in children with long-standing untreated idiopathic subclinical hypothyroidism. J Clin Endocrinol Metab. 2014;99(8):2697-2703.
Nader NS, Bahn RS, Johnson MD, Weaver AL, Singh R, Kumar S. Relationships between thyroid function and lipid status or insulin resistance in a pediatric population. Thyroid. 2010;20(12):1333-1339.
Radetti G, Grugni G, Lupi F, et al. The relationship between hyperthyrotropinemia and metabolic and cardiovascular risk factors in a large group of overweight and obese children and adolescents. J Endocrinol Invest. 2017;40(12):1311-1319.
Olesen P, Ledet T, Rasmussen LM. Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-alpha. Diabetologia. 2005;48(3):561-568.
Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89(2):309-319.
Collin-Osdoby P. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res. 2004;95(11):1046-1057.
Perez de Ciriza C, Lawrie A, Varo N. Osteoprotegerin in Cardiometabolic Disorders. Int J Endocrinol. 2015;2015:564934.
Anand DV, Lim E, Darko D, et al. Determinants of progression of coronary artery calcification in type 2 diabetes role of glycemic control and inflammatory/vascular calcification markers. J Am Coll Cardiol. 2007;50(23):2218-2225.
Avignon A, Sultan A, Piot C, et al. Osteoprotegerin: a novel independent marker for silent myocardial ischemia in asymptomatic diabetic patients. Diabetes Care. 2007;30(11):2934-2939.
Aoki A, Murata M, Asano T, et al. Association of serum osteoprotegerin with vascular calcification in patients with type 2 diabetes. Cardiovasc Diabetol. 2013;12:11.
Abedin M, Omland T, Ueland T, et al. Relation of osteoprotegerin to coronary calcium and aortic plaque (from the Dallas Heart Study). Am J Cardiol. 2007;99(4):513-518.
Miura M, Tanaka K, Komatsu Y, et al. A novel interaction between thyroid hormones and 1,25(OH)(2)D(3) in osteoclast formation. Biochem Biophys Res Commun. 2002;291(4):987-994.
Kanatani M, Sugimoto T, Sowa H, Kobayashi T, Kanzawa M, Chihara K. Thyroid hormone stimulates osteoclast differentiation by a mechanism independent of RANKL-RANK interaction. J Cell Physiol. 2004;201(1):17-25.
Nagasaki T, Inaba M, Jono S, et al. Increased levels of serum osteoprotegerin in hypothyroid patients and its normalization with restoration of normal thyroid function. Eur J Endocrinol. 2005;152:347-353.
Guang-da X, Hui-ling S, Jie H. Changes in endothelial function and its association with plasma osteoprotegerin in hypothyroidism with exercise-induced silent myocardial ischaemia. Clin Endocrinol. 2008;69:799-803.
Konca Degertekin C, Turhan Iyidir O, Aktas Yilmaz B, et al. RANKL/Osteoprotegerin system and bone turnover in hashimoto thyroiditis. Calcif Tissue Int. 2016;99(4):365-372.
Crisafulli G, Aversa T, Zirilli G, et al. Subclinical hypothyroidism in children: when a replacement hormonal treatment might be advisable. Front Endocrinol. 2019;10:109.
Capalbo D, Alfano S, Polizzi M, et al. Cognitive function in children with idiopathic subclinical hypothyroidism: effects of 2 years of levothyroxine. Therapy. J Clin Endocrinol Metab. 2020;105:3.
Cerbone M, Capalbo D, Wasniewska M, et al. Effects of L-thyroxine treatment on early markers of atherosclerotic disease in children with subclinical hypothyroidism. Eur J Endocrinol. 2016;175(1):11-19.
Fonseca V, Guba SC, Fink LM. Hyperhomocysteinemia and the endocrine system: implications for atherosclerosis and thrombosis. Endocr Rev. 1999;20(5):738-759.
Aversa T, Valenzise M, Corrias A, et al. Underlying Hashimoto's thyroiditis negatively affects the evolution of subclinical hypothyroidism in children irrespective of other concomitant risk factors. Thyroid. 2015;25(2):183-187.
Wasniewska M, Aversa T, Salerno M, et al. Five-year prospective evaluation of thyroid function in girls with subclinical mild hypothyroidism of different etiology. Eur J Endocrinol. 2015;173(6):801-808.